Table 4.

Network meta‐analysis of PFS in overall population.

Niraparib
1.1 (0.72, 1.6)	Olaparib
0.74 (0.47, 1.2)	0.69 (0.41, 1.2)	Olaparib-throughout
1.0 (0.76, 1.4)	0.95 (0.64, 1.4)	1.4 (0.88, 2.2)	Rucaparib
0.38 (0.30, 0.48)	0.35 (0.25, 0.49)	0.51 (0.34, 0.76)	0.37 (0.30, 0.45)	Placebo

Results in each cell represent the pooled HR and its 95% CrI. The estimates are located at the crossing between the column‐defining treatment and row‐defining treatment. An HR lower than one favors the column‐defining treatment. The significant results are presented in bold.